 |
BioWorld-International-2009-12-16
Molecular Partners Gets $44M for its Rapid DARPin Scaffolds
Molecular Partners Gets $44M for its Rapid DARPin Scaffolds
Molecular Partners AG, which is commercializing a protein scaffold technology, raised CHF46 million (US$44.2 million) in a Series B financing round led by Essex Woodlands Health Ventures, taking its total investment raised in the past two and a half years to CHF64.5 million.(BioWorld International)
Intercell Gets €62M for Starters in GSK Vaccine Patch Alliance
No Abstract
BioWorld International Correspondent
Intercell AG is strengthening an already solid cash position of €139.7 million (US$203 million) by immediately adding another €62 million, thanks to a wide-ranging strategic alliance with the GSK Biologicials arm of GlaxoSmithKline plc, based on its needle-free, patch-based vaccine in development for travelers' diarrhea and its enhancement patch for pandemic flu vaccines. It also stands to gain a share of the profits from global sales of the two products.